Commented Articles

PanNASH covers commented articles ans publications to acquire sufficient information, understanding, and skills to cope with NASH/NAFLD healthcare demands.

Experimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.

In a CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis, S. Lefere et al. studied the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. To examine the pathophysiological sequence of steatohepatitis...
Read MoreExperimental steatohepatitis: lanifibranor early reduces NASH activity and macrophage infiltration.

Clinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.

A. de Gottardi et al. (Gastroenterology and Hepatology, Ente Ospedaliero Cantonale, Lugano, Switzerland) present a case of SARS-CoV-2 infection reported in the literature in a liver transplanted patient. In this immunosuppressed patient, the evolution of the infection was characterized by a moderate to severe interstitial pneumonia...
Read MoreClinical characteristics and management of a liver transplanted patient admitted with SARS-CoV-2 infection.

Differential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.

In an experimental study, S. Lefere et al. investigated the efficacy of single and pan-PPAR agonists in the treatment of progressive steatohepatitis. The authors employed the CDAA-HFD (choline-deficient, amino acid-defined high-fat diet-induced) model, which induces severe inflammation and liver fibrosis...
Read MoreDifferential effects of selective- and pan-PPAR agonists on experimental steatohepatitis and hepatic macrophages.

Physical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Nowadays, dramatic changes in the lifestyle and diet of the global population are causing the prevalence of NAFLD increasing rapidly, in parallel with that of obesity and diabetes. Previous studies found an inverse relationship between physical activity and the risk of NAFLD. However, clinical trials...
Read MorePhysical activity intervention for non-diabetic patients with non-alcoholic fatty liver disease: a meta-analysis of randomized controlled trials.

Human hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

In this study, J. Boeckmans et al. (Faculty of Medicine and Pharmacy, Vrije Universiteit, Brussels, Belgium) reproduced key NASH characteristics in vitro by exposing primary human hepatocytes, human skin stem cell-derived hepatic cells, HepaRG and HepG2 cell lines, as well as LX-2 hepatic stellate cells to multiple factors that play a role in the onset of NASH...

Read MoreHuman hepatic in vitro models reveal distinct anti-NASH potencies of PPAR agonists.

Awareness of Non-alcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

Low awareness can delay healthcare screening and prevention of NAFLD and its related complications. Therefore, low awareness of NAFLD among the general population is a matter of great concern. This is also important for resource allocation, and the creation and implementation of awareness programs....
Read MoreAwareness of Non-alcoholic Fatty Liver Disease Is Increasing but Remains Very Low in a Representative US Cohort.

Effects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

Some studies showed that the effect of SGLT2 inhibitors on weight loss was useful for the alleviation of NAFLD and SGLT2 inhibitors can significantly reduce bodyweight in NAFLD patients. In addition, a recent cohort study suggested that the administration of SGLT2 inhibitors to patients with type 2 diabetes mellitus could...
Read MoreEffects of sodium-glucose cotransporter 2 inhibitors on non-alcoholic fatty liver disease in patients with type 2 diabetes: A meta-analysis of randomized controlled trials.

The amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease.

NAFLD is closely related to features of the metabolic syndrome including type 2 diabetes. P. Nasr et al. (Linköping University, Sweden) investigated the importance of the amount of liver fat on mortality and the risk of developing type 2 diabetes. In 129 patients with biopsy proven NAFLD prospectively...
Read MoreThe amount of liver fat predicts mortality and development of type 2 diabetes in non-alcoholic fatty liver disease.

Correlation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease.

J. Cai et al. (Department of Geriatric Medicine, Zhongshan Hospital, Xiamen, P.R. China) investigated changes in the level of serum 25-OH vitamin D [25-hydroxyvitamin D, 25(OH)D] in patients with NAFLD and the correlation between the severity of NAFLD and 25(OH)D. Their retrospective analysis was performed on 385 NAFLD patients and 347 healthy people...
Read MoreCorrelation between serum 25-OH vitamin D expression and non-alcoholic fatty liver disease.

Cilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial.

Cilofexor is a small molecule nonsteroidal agonist of farnesoid X receptor (FXR). K. Patel et al. (University of Toronto, Canada) evaluated the safety and efficacy of cilofexor in patients with NASH in a double-blind, placebo-controlled, phase 2 trial. 140 non-cirrhotic patients with NASH were randomized to receive cilofexor...
Read MoreCilofexor, a Nonsteroidal FXR Agonist, in Non-Cirrhotic Patients with Nonalcoholic Steatohepatitis: A Phase 2 Randomized Controlled Trial.

Selonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials

Apoptosis signal-regulating kinase 1 (ASK1) plays a key role in hepatocyte injury, inflammation, and fibrosis in nonalcoholic steatohepatitis (NASH). Selonsertib is an investigational selective inhibitor of ASK1. In order to evaluate the safety and anti-fibrotic effect of selonsertib, Stephen A. Harrison et al...
Read MoreSelonsertib for patients with bridging fibrosis or compensated cirrhosis due to NASH: Results from randomized phase III STELLAR trials